Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX2011 vs Paclitaxel (Albumin-bound) in Advanced Breast Cancer
NCT05753865Phase 3Unknown
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- May 2023
- Primary completion
- Sep 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SYHX-2011 in breast cancer (2 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
SYHX-2011
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05753865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753865.